Jiang Guangyi, Hong Junjie, Shao Feng, Wen Qiang, Cheng Feng, Yu Tunan, Zhu Jianqing
Department of Gynecological Oncology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Front Oncol. 2022 Feb 24;12:795129. doi: 10.3389/fonc.2022.795129. eCollection 2022.
Ovarian tumors are among the most prominent gynecological malignancies and have a poor prognosis. Immunotherapy has undergone incredible progress in the past two decades. Our study aimed to use a bibliometric approach to identify research trends in ovarian cancer immunotherapy.
Literature on this topic published from 2000-2020 was retrieved from the Web of Science Core Citation database and analyzed using the bibliometric analysis software VOSviewer and CiteSpace.
A total of 1729 articles on ovarian cancer immunotherapy published from January 2000 to December 2020 were identified. The number of published articles increased each year, from 40 in 2000 to 209 in 2020. These publications were from 61 countries, and the USA showed a dominant position in publication output, total citations, and average number of citations per paper. Co-citation networks revealed 14 subtopics. 'PD-L1 expression,' 'tumor reactive til,' and 'parp inhibitor' are the current potential subtopics. Furthermore, we determined research trends according to the timeline analysis.
Our study exhaustively describes the development and summarizes the research trends of ovarian cancer immunotherapy over the past 20 years.
卵巢肿瘤是最常见的妇科恶性肿瘤之一,预后较差。在过去二十年中,免疫疗法取得了惊人的进展。我们的研究旨在使用文献计量学方法来确定卵巢癌免疫疗法的研究趋势。
从科学网核心引文数据库中检索2000 - 2020年发表的关于该主题的文献,并使用文献计量分析软件VOSviewer和CiteSpace进行分析。
共识别出2000年1月至2020年12月发表的1729篇关于卵巢癌免疫疗法的文章。发表文章的数量逐年增加,从2000年的40篇增加到2020年的209篇。这些出版物来自61个国家,美国在发表量、总被引频次和每篇论文平均被引频次方面占据主导地位。共被引网络揭示了14个主题。“PD - L1表达”“肿瘤反应性til”和“PARP抑制剂”是当前潜在的主题。此外,我们根据时间线分析确定了研究趋势。
我们的研究详尽地描述了过去20年卵巢癌免疫疗法的发展并总结了研究趋势。